OAB Anticholinergics: Does Treating the Bladder Put the Brain at Risk? A tweet-itorial 🧵 inspired by my @NCSAUA open mic earlier this AM... *disclaimer = this topic is rich and nuanced, this 🧵 is not exhaustive

Take a few minutes to read this amazing article 📚 First in Human Subjects Testing of the UroMonitor: A Catheter-free Wireless Ambulatory Bladder Pressure Monitor Click here ➡️ https://t.co/TBFW3lFnPV or click the link in our bio!

1🧵 about our newest publication on the topic of destroyed bladders (progressive inflammatory cystitis - PIC) https://t.co/3JSPlbDMBe @AnnePCameron's idea: pts w/end stage bladders but no underlying etiology... A dive @UMichUrology & @UMichPath to explore ensued..@anna_faris12

Thank you to AUA and SUFU for letting us participate in this update. Got to do this with rockstars @KKseattle @RenaMalikMD. This update represents the most current body of literature on SUI. @sufuorg #AUA2023

Thank you for highlighting! >33M Americans suffer from OAB, and ACh💊 remain the most Rx-ed OAB tx. Hope this provides helpful info re: our current understanding of potential 🧠 risks and nuances to guide convos with pts and rx decision-making !

We are so excited to welcome Grace Prillaman and Bard Kennady as our newest UVA Urology residents! 🎉 Happy match day, everybody! #uva #urology #uvaurology #uromatch2023 #AUAmatch @grace_prill @EBardKennady

Could not have said it better. #FPMRS is a versatile and richly rewarding field - and the @CleClinicUro fellowship is hands down fantastic. As a recent alum, already so grateful for the training and relationships!

If doing pioneering research or mastering the breath/depth of #FPMRS surgeries makes you do the happy nerd dance 🤓, consider applying to our fellowship! Last day to apply Tuesday @CleClinicUro. Happy to chat/answer questions🙂@SandipVasavada @EmilySlopnickMD HGoldman RRackley

👇👇👇 @BernieSanders @LeaderMcConnell @AOC @SenSchumer We are standing buy to save taxpayers money. Waiting on each of you to do your part !

https://t.co/XAB95hQYgh

So GSM ttt does not work because it is simply does not work...rather it is not taken! #sexmed22

Impostor syndrome is not a sign that other people are overestimating you. It's more likely that you're underestimating your potential. Confidence is often a consequence of growth, not a cause. Believing in your ability is less important than believing in your ability to improve.

We're so proud of our residents Drs. Yeaman & Ballantyne for winning the resident prize essay contest at this year's @MidAtlanticAUA annual meeting! 🎉🏆@ClintYeaman #uva #urology #uvaurology #MAAUAA22

#SUFU OAB medications and dementia risk: https://t.co/lO6xvT4opy @jmzilla @bkwelk @Uro_KIND @AnnGormley1 Dr. Howard B Goldman

Still many outstanding ❓on the issue; however, compelling concerns raised by avail evidence support preferential use of other effective, low-risk options. Cost is major hurdle & patients/clinicians may elect to use OAB AC meds for their benefits despite potential 🧠risks

6. Consider progressing to advanced therapy (botulinum, neuromodulation) earlier in OAB treatment paradigm

4. When using OAB ACs, avoid oxybutynin IR and prefer those with more favorable neuropharm profiles (i.e., trospium) 5. Consider potential cognitive risks in ALL patient populations when prescribing OAB ACs for chronic use ...

In brief... 1. Chronic (>3mo) use OAB AC likely assoc w increase risk of new-onset dementia 2. Short term (<4 weeks) use of non-oxybutynin IR likely safe in most pts 3. When meds indicated for OAB, trial of beta-3 agonist is typically preferred ...

Very excited to share this @sufuorg white paper on OAB anticholinergics & dementia risk. We aimed to offer concise, practical clinical guidance in context of current lit. @bkwelk @Uro_KIND @AnnGormley1 @NeurourolUrodyn https://t.co/3pCEPrngWU

p.s. who knew that chief grad pic would come in handy a few years later?

Very excited to be back and get to work!